



PRESS RELEASE - 13 JUNE 2007

Michael Oredsson appointed CEO of Probi

Michael Oredsson has been appointed Chief Executive Officer of Probi AB. Mr. Oredsson has been CEO of listed Australian biotech corporation Biosignal since February 2002, where he headed the company's growth and listing on the Sydney Stock Exchange.

"Probi has great products with sizeable future opportunities and skilled employees," commented Mr. Oredsson, "I look forward to taking up the challenge of continuing to develop the company and realizing the potential of the impressive research portfolio."

Under Mr. Oredsson's leadership, Biosignal, which offers an entirely new antibacterial technology, successfully signed a series of R&D and licensing agreements with global medical and industrial corporations. In 1999-2001, Michael was CEO of the Norwegian biotech company Nutripharma, where he had a key role in its IPO and build-up into an international corporation. Nutripharma also signed a number of licensing agreements with global food corporations under his management.

"I'm delighted that Michael has accepted the offer to be the new CEO of Probi," commented Peter Zakrisson, Probi's Chairman, "Michael has extensive experience of building and developing businesses in the biotech sector. His proven capacity to lead and build businesses, plus his experience of international sales and marketing, makes him very well suited to take Probi to the next level of its development."

Michael's previous responsibilities included building Pharmacia's Australian OTC products division from scratch, plus a series of senior marketing executive positions for Nestlé and Mars Inc. in Sweden, Germany and France.

Rolf Bjerndell will remain Probi's acting CEO until Mr. Oredsson takes up his position, which is scheduled for the early autumn. Per-Ola Forsberg will continue as Executive Vice President in the company.

For further information, please contact:

Peter Zakrisson, Chairman of the Board, ph: +46-8-545 680 61 or mobile +46-709-50 96 20
Michael Oredsson, ph: +61414385064 or email m.oredsson@biosignal.com.au

About Probi

Probi was founded in 1991 and is now one of the world's leading companies in the field of probiotic R&D. The company's research focuses on live micro-organisms with scientifically demonstrated health-promoting effects. The main R&D fields are gastrointestinal disorders, the immune system, cardiovascular diseases, and stress and performance recovery. Probi's business is based on offering effective and thoroughly documented probiotic products and concepts, protected by comprehensive patents. This yields higher revenue levels than for the industry as a whole. Probi has enjoyed a consistent income stream from commercialised products since the mid-1990s. The customers comprise leading international companies in the fields of functional food, dietary supplements and clinical nutrition. The global market for probiotic products is showing good underlying growth while new insights into the benefits offered by probiotics are boosting the market still further. Increased documentation requirements and official regulation are two trends that tend to give Probi an edge on its competitors. Probi is based in Lund and has 17 employees. The Probi share is quoted on the Nordic Stock Exchange. For more information, please visit www.probi.com